CoChat

Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers

Ebert, Ulrike, Grossmann, Matthias, Oertel, Reinhard, Gramatté, Thomas, Kirch, Wilhelm · 2001 · The Journal of Clinical Pharmacology
Cited by 63

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Scopolamine is a muscarinic receptor antagonist commonly used as a pharmacological model substance based on the “cholinergic hypothesis” of memory loss in senile dementia of the Alzheimer type. The objective of the study was to relate pharmacodynamic electroencephalogram (EEG) changes and scopolamine serum concentration using pharmacokinetic‐pharmacodynamic (PK‐PD) modeling techniques. This was a randomized, three‐way crossover, open‐label study involving 10 healthy nonsmoking young male volunteers who received either scopolamine 0.5 mg as an intravenous (IV) infusion over 15 minutes or an intramuscular (IM) injection oraplacebo. The pharmacodynamic EEG measure consists of the total power in delta, theta, alpha, and beta bands over frontal, central, and occipital brain areas. The values of the pharmacokinetic parameters of scopolamine after IV infusion were clearance (CL) 205 ± 36.6 L/h, volume of distribution (Vd) 363 ±66.7 L, distribution half‐life (t 1/2α) 2.9±0.67 min, and terminal half‐life (t 1/2β) 105.4 ±9.94 min (mean ± SEM). Mean peak serum concentrations (C max) were 4.66 and 0.96 ng/ml after IV and IM administration, respectively (p < 0.05). The area under the serum concentration versus time curve (AUC) after IM administration (81.27±11.21 ng/ml/min) was significantly lower compared to the value after IV infusion (157.28 ±30.86 ng/ml/min) (mean ±SEM, p < 0.05). Absolute bioavailability of scopolamine after IM injection was 57% ±0.08% (mean ±SEM). After both IV and IM administration, scopolamine induced a decrease in EEG alpha power (7.50‐11.25 Hz) over frontal, central, and occipital brain areas compared to placebo (p < 0.05). The individual concentration‐EEG effect relationships determined after IV infusion of scopolamine were successfully characterized by a sigmoidal E max model. The averaged values of the pharmacodynamic parameters were E 0 = 0.58 μV 2, E max = 0.29 μV 2, EC 50 = 0.60 ng/ml, and γ = 1.17. No time delay between serum concentrations and changes in alpha power was observed, indicating a rapid equilibration between serum and effect site. The results provide the first demonstration of a direct correlation between serum concentrations of scopolamine and changes in total power in alpha frequency band in healthy volunteers using PK‐PD modeling techniques. As regards the effect on the EEG, 0.5 mg of scopolamine administered IV appears to be a suitable dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/00912700122009836

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 63

Metadata

Authors
Ebert, U., Grossmann, M., Oertel, R., Gramatté, T., & Kirch, W.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2001-01
Volume
41
Issue
1
Pages
51-60
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2125999113
Cited by
63
References
2
FWCI
0.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers. https://app.cochat.ai/papers/10.1177/00912700122009836
The paper
Ebert, U., Grossmann, M., Oertel, R., Gramatté, T., & Kirch, W. (2001). Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912700122009836

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.